A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-17

Study Completion Date

2016-12-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tuberculous meningitis is a severe brain infection which often causes disability and death even when treated with the best available treatment. Aspirin is a type of anti-inflammation drug which can reduce the inflammatory response in brains of patients with tuberculous meningitis, and therefore may decrease some of the most severe outcomes. This study compares the use of aspirin (at 2 different doses) versus placebo as an additional therapy to the standard treatment to see if aspirin is safe and helpful in reducing disability and death from tuberculous meningitis. Patients will be treated with aspirin or placebo for 60 days and followed up while on standard treatment for 8 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)

NCT03092817

Tuberculosis Tuberculous Meningitis Drug-Induced Liver Injury +2 more

COMPLETED PHASE3

Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment

NCT00737724

HIV AIDS Tuberculosis

TERMINATED NA

Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment

NCT01417988

HIV Infection Tuberculosis

TERMINATED PHASE4

Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis

NCT00108862

HIV Infection Tuberculosis

COMPLETED PHASE4

Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis

NCT00376012

Tuberculosis Human Immunodeficiency Virus Infections

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a parallel group, double blind, randomised, placebo controlled trial of 60 days treatment with placebo vs. 81mg daily dose vs. 1000mg daily dose aspirin for the treatment of HIV-uninfected adults with tuberculous meningitis.

All patients will receive standard anti-tuberculous chemotherapy and adjunctive dexamethasone, according to Viet Nam National Tuberculosis Programme guidelines. Participants will be stratified by Medical Research Council UK disease severity grade, and randomized at enrollment to one of three study arms (1:1:1 ratio). Patients will be admitted to hospital for at least the first 14 days of study treatment enabling real-time active surveillance of any adverse events after which they will be discharged according to clinical care with continued monitoring.

A schedule of clinical and laboratory monitoring including lumbar puncture, pharmacokinetic assessment of peripheral blood monocyte/macrophage antimicrobial activity, clinical assessments, brain magnetic resonance imaging (MRI) and neurological assessment will manage patient safety and capture study outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculous Meningitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

81mg aspirin

Aspirin 81mg daily for 60 days

Group Type EXPERIMENTAL

81mg aspirin

Intervention Type DRUG

1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days

1000mg aspirin

Aspirin 1000mg daily for 60 days

Group Type EXPERIMENTAL

1000mg aspirin

Intervention Type DRUG

1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days

Placebo

Visually matched placebo daily for 60 days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

81mg aspirin

1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days

Intervention Type DRUG

1000mg aspirin

1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days

Intervention Type DRUG

Placebo

1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, aged 18 years or above.
* Suspected TBM and anti-tuberculosis chemotherapy either planned or started
* Less than 3 days of anti-tuberculosis chemotherapy taken for the current infection
* Patient or representative (if the patient is unable) is willing and able to give informed consent for participation in the study.

Exclusion Criteria

* HIV infection (negative rapid test or Elisa test is required)
* Unlikely, for any reason, to be able to have an MRI brain scan within 5 days (120 hours) of randomisation
* Known or suspected infection with multi-drug resistant tuberculosis (resistant to at least isoniazid and rifampicin)
* Unable to take isoniazid, rifampicin, or pyrazinamide at recommended doses for any reason
* History of diagnosed peptic ulceration or gastro-intestinal bleeding
* Active gastro-intestinal bleeding is suspected
* Taken \>1 dose of aspirin (at any dose) or any other non-steroidal anti-inflammatory drugs for any reason within 2 weeks of screening
* Aspirin considered mandatory for any reason by the attending physician
* Aspirin considered to be contraindicated for any reason by the attending physician
* Pregnancy or breast feeding (negative urine pregnancy test for all females of child-bearing age)
* Dexamethasone considered to be contraindicated for any reason by the attending physician
* Any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No